New markers targeting neuroendocrine neoplasms NENs
A neuroendocrine neoplasm (NEN) begins in the cells of the neuroendocrine system. These cells have traits of both hormone-producing endocrine cells and nerve cells. The advent of second-generation NEN markers for use in immunohistochemistry has considerably expanded the pathology toolbox for diagnosing and classifying NENs. Atlas Antibodies has released new monoclonal markers targeting NENs. Read more in our new blog post!
Interview with a scientist: immune resistance in lung cancer
In our new ”Interview with a Scientist” blog post, we asked Antonio Marzio, Ph.D., about his research on the mechanisms that drive immune-resistant responses in patients with non-small-cell lung carcinoma (NSCLC). Read on to learn more!
Research Roundup: cancer research
Our new Research Roundup summarises three cancer research studies that have used polyclonal antibodies from Atlas Antibodies. Today we share insights into a new biomarker for glioma, the metastatic process in colorectal cancer, and the effect of ginseng metabolites on cancer cells proliferation. Learn more!
Five questions to better understand T-cell receptors therapy
T-Cell receptors therapy is a growing area of immuno-oncology with recent breakthroughs in clinical settings, thereby demonstrating his therapeutic potential in mitigating tumor development. So what do you know about T-Cell therapy? Read on! Dr. Erika von Euw from T-Cure Bioscience help us to understand it better.
Ion channels as promising biomarkers in cancer
In this blog post, we share bits of evidence about the involvement of voltage-gated ion channels in human cancers, highlighting their promising use as biomarkers. Read on!
Research Roundup: diagnostic and prognostic cancer markers
Are you interested in seeing more of our antibodies in action? The following three studies have successfully utilized our antibodies to suggest or identify new biomarkers for different human cancers. Keep reading.
Research Roundup: prognostic biomarkers in cancer
Many of our cancer antibodies are used in cutting-edge research to identify new prognostic markers in different cancers. Let's take a look at three recent studies.
Interview with a scientist: drug repurposing in oncology
Drug repurposing is the strategy of using existing drugs originally developed for a specific disease to treat other diseases. We have interviewed Dr. Joanna Zawacka-Pankau about her research in drug repurposing to treat cancer.
Liquid biopsy: what is written in the blood?
Liquid biopsy is a non-invasive sampling approach also used to predict the progression and growth dynamics of cancer and provide guidance for therapy monitoring. This blog covers various features and issues associated with liquid biopsy as exemplified by tumor markers.
Candidate diagnostic biomarkers for lung cancer
In this blog, we discuss the rapidly evolving field of targeted drug therapy in lung cancer.
Keep reading to learn more!